Wemodel theeventofinterest asaspecial terminal state, andwe seek to estimate the survival distribution (i.e., the distribution of the hitting time for that terminal state) from anyother state.

This study presents a comparative methodological analysis of six machine learning models for survival analysis (MLSA). Using data from nearly 45,000 colorectal cancer patients in the Hospital-Based Cancer Registries of São Paulo, we evaluated Random Survival Forest (RSF), Gradient Boosting for Survival Analysis (GBSA), Survival SVM (SSVM), XGBoost-Cox (XGB-Cox), XGBoost-AFT (XGB-AFT), and LightGBM (LGBM), capable of predicting survival considering censored data. Hyperparameter optimization was performed with different samplers, and model performance was assessed using the Concordance Index (C-Index), C-Index IPCW, time-dependent AUC, and Integrated Brier Score (IBS). Survival curves produced by the models were compared with predictions from classification algorithms, and predictor interpretation was conducted using SHAP and permutation importance. XGB-AFT achieved the best performance (C-Index = 0.7618; IPCW = 0.7532), followed by GBSA and RSF. The results highlight the potential and applicability of MLSA to improve survival prediction and support decision making.

Abstract--Ride-hailing platforms are characterized by high-frequency, behavior-driven environments, such as shared mobility platforms. Although survival analysis has been widely applied to recurrent events in other domains, its use for modeling ride-hailing driver behavior remains largely unexplored. T o the best of our knowledge, this study is the first to formulate driver idle behavior as a recurrent survival process using large-scale platform data. This study proposes a survival analysis framework that uses a Transformer-based temporal encoder with causal masking to capture long-term temporal dependencies and embeds driver-specific embeddings to represent latent individual characteristics, significantly enhancing the personalized prediction of driver retention risk, modeling how historical idle sequences influence the current risk of leaving the platform via trip acceptance or log-off. The model is validated on datasets from the City of T oronto over the period January 2 to March 13, 2020. The results show that the proposed Frailty-A ware Cox Transformer (F ACT) delivers the highest time-dependent C-indices and the lowest Brier Scores across early, median, and late follow-up, demonstrating its robustness in capturing evolving risk over a driver's lifecycle. This study enables operators to optimize retention strategies and helps policy makers assess shared mobility's role in equitable and integrated transportation systems. The purpose of this study is to model the driver retention behavior through a transformer-based survival model. Shared mobility services, such as ride-hailing, car-sharing, and bike-sharing, are becoming an increasingly prominent component of contemporary transportation systems. These services are central to the broader concept of Mobility as a Service (MaaS) [1], which aims to integrate various forms of transport into a unified and user-centric platform.

Survival analysis is critical for cancer prognosis and treatment planning, yet existing methods lack the transparency essential for clinical adoption. While recent pathology agents have demonstrated explainability in diagnostic tasks, they face three limitations for survival prediction: inability to integrate multimodal data, ineffective region-of-interest exploration, and failure to leverage experiential learning from historical cases. We introduce SurvAgent, the first hierarchical chain-of-thought (CoT)-enhanced multi-agent system for multimodal survival prediction. SurvAgent consists of two stages: (1) WSI-Gene CoT-Enhanced Case Bank Construction employs hierarchical analysis through Low-Magnification Screening, Cross-Modal Similarity-Aware Patch Mining, and Confidence-Aware Patch Mining for pathology images, while Gene-Stratified analysis processes six functional gene categories. Both generate structured reports with CoT reasoning, storing complete analytical processes for experiential learning. (2) Dichotomy-Based Multi-Expert Agent Inference retrieves similar cases via RAG and integrates multimodal reports with expert predictions through progressive interval refinement. Extensive experiments on five TCGA cohorts demonstrate SurvAgent's superority over conventional methods, proprietary MLLMs, and medical agents, establishing a new paradigm for explainable AI-driven survival prediction in precision oncology.

Survival prediction is a significant challenge in cancer management.

Pathology whole-slide images (WSIs) are widely used for cancer survival analysis because of their comprehensive histopathological information at both cellular and tissue levels, enabling quantitative, large-scale, and prognostically rich tumor feature analysis. However, most existing methods in WSI survival analysis struggle with limited interpretability and often overlook predictive uncertainty in heterogeneous slide images. In this paper, we propose DPsurv, a dual-prototype whole-slide image evidential fusion network that outputs uncertainty-aware survival intervals, while enabling interpretation of predictions through patch prototype assignment maps, component prototypes, and component-wise relative risk aggregation. Experiments on five publicly available datasets achieve the highest mean concordance index and the lowest mean integrated Brier score, validating the effectiveness and reliability of DPsurv. The interpretation of prediction results provides transparency at the feature, reasoning, and decision levels, thereby enhancing the trustworthiness and interpretability of DPsurv. Survival analysis, which predicts survival probabilities and outcomes over time, is a critical task in oncology for guiding therapeutic decision-making and improving patient outcomes. As a direct reflection of tumor progression, whole-slide images (WSIs) have recently emerged as an essential source of information for survival prediction in computational pathology (Zhang et al., 2025). The major challenges for identifying reliable prognostic patterns from WSIs lie in the gigapixel scale and the tissue heterogeneity (Wang et al., 2022; Xu et al., 2024). Failing to model and address these challenges can result in incomplete risk assessments, leading to suboptimal treatment planning and potentially compromised survival outcomes (Liu et al., 2025b; Shi et al., 2024b).

Survival analysis using whole-slide images (WSIs) is crucial in cancer research. Despite significant successes, pathology images typically only provide slide-level labels, which hinders the learning of discriminative representations from gigapixel WSIs. With the rapid advancement of high-throughput sequencing technologies, multimodal survival analysis integrating pathology images and genomics data has emerged as a promising approach. We propose a Multi-Expert Mamba (ME-Mamba) system that captures discriminative pathological and genomic features while enabling efficient integration of both modalities. This approach achieves complementary information fusion without losing critical information from individual modalities, thereby facilitating accurate cancer survival analysis. Specifically, we first introduce a Pathology Expert and a Genomics Expert to process unimodal data separately. Both experts are designed with Mamba architectures that incorporate conventional scanning and attention-based scanning mechanisms, allowing them to extract discriminative features from long instance sequences containing substantial redundant or irrelevant information. Second, we design a Synergistic Expert responsible for modality fusion. It explicitly learns token-level local correspondences between the two modalities via Optimal Transport, and implicitly enhances distribution consistency through a global cross-modal fusion loss based on Maximum Mean Discrepancy. The fused feature representations are then passed to a mamba backbone for further integration. Through the collaboration of the Pathology Expert, Genomics Expert, and Synergistic Expert, our method achieves stable and accurate survival analysis with relatively low computational complexity. Extensive experimental results on five datasets in The Cancer Genome Atlas (TCGA) demonstrate our state-of-the-art performance.